News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

The Logic of Biologics - Is Regeneron Pharmaceuticals, Inc. (REGN) the Next Genentech (RHHBY)?


5/22/2013 9:00:02 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

When the US biotech company Regeneron Pharmaceuticals recently announced its first-quarter results, few were surprised that the company’s flagship wet age-related macular degeneration (AMD) product Eylea had once again exceeded consensus expectations. With three-monthly sales of $314 million, management reiterated that full-year revenues for 2013 are expected to hit $1.3 billion.

Hey, check out all the research scientist jobs. Post your resume today!

Read at Forbes


comments powered by Disqus
Forbes
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES